http://www.medscape.com/viewarticle/844707_6




Perioperative Fluid Management: Science, Art or Random Chaos?

G. Minto; M. G. Mythen

 Disclosures

Br J Anaesth. 2015;114(5):717-721. 

Introduction

As anaesthetists, we like to believe that the i.v. fluid we administer during surgery is based on a careful consideration of the contemporaneous clinical situation in the particular individual under our care. We estimate deficits; we use clinical assessment and haemodynamic monitoring to characterize circulating blood volume, and we respond to changes with fluid challenges and vasopressors.

A recently proposed framework within which to consider fluid therapy for acutely ill patients (including those where the 'acute illness' is the stress of major surgical resections) emphasizes that fluid needs differ depending on which of the following four phases is relevant at the time: (i) salvage (resuscitation); (ii) optimization; (iii) stabilization; or (iv) de-escalation.[1]

In haemodynamic situations that are likely to incorporate resuscitation and optimization phases (such as trauma or sepsis), the individual requirements may vary greatly. Contemporary surgery, often with minimal access or laparoscopically assisted, probably triggers much less physiological stress response fluid shift than surgery of 15 yr ago.[2] The notion that major surgery triggers 'a loss of fluid to third space'[3] holds no foundation. Systematic review shows that the evidence for a disparate reduction of the extracellular fluid volume following trauma or surgery is weak and that this long held belief is probably a result of flawed methodology.[4]

Thus, with modern elective resection techniques, physiological disruption is minimized and fluid shifts are rare. Fluid therapy in this setting is predominantly for optimization and stabilization. If we are as good as we think we are at perioperative fluid therapy, then in such patients we would expect to see consistency in the volume we give; individual providers might differ somewhat in how they interpret the haemodynamic variables, but in general, for any particular operation we should see a fairly narrow range of i.v. fluid volumes used.

Well, apparently not! A retrospective observational study in this issue of the BJA reports intraoperative fluid therapy practices at two US academic hospitals.[5] In a database of 5912 patients having common types of abdominal surgery, the authors found great variability in the amounts of crystalloid administered. The average corrected infusion rate across all providers at both hospitals was 7.1 (SD4.9) ml kg−1 h−1. A sophisticated linear regression was then used to identify explanatory factors for the volumes given. In the final model, the most important predictor by far was the provider of anaesthesia. Other variables included in the analysis were many of the end points that we surmise perioperative physicians might be using to judge fluid therapy, and these hardly seemed to matter. Factors such as minimum or median mean arterial pressure and median heart rate during surgery, estimated blood loss, surgical approach, and surgical type had either relatively weak or no effects in the final model in comparison to who was giving the fluid. The summary message is that fluid administration was largely according to the individual provider's 'habit', or that there was great inconsistency in the way that providers interpret and respond to haemodynamic and clinical signals during surgery.

In some instances, there was even wide intraprovider variability. A modified corrected coefficient of variation (cCOV) was used to express the range seen across institutions, procedures, and providers. This was calculated by dividing the sample SD (say, of all the cases of a particular provider) by the mean of the entire cohort (7.1 ml kg−1 h−1). The lowest provider cCOV was 26% (consistent fluid administration across many cases) and the highest 141% (very inconsistent). In an applied example, the authors showed how a patient weighing 75 kg undergoing a 4 h procedure with minimal blood loss could receive anything between 700 and 5400 ml of crystalloid during surgery, depending on their anaesthesia provider.

Critics might say this is because of individual variability of the cases, many details of which may be invisible at registry level; however, the authors have taken great care to identify in their data set only those patients undergoing uncomplicated abdominal surgery under general anaesthetic, the underlying philosophy being to eliminate as much as possible the interpatient differences in the pathophysiological and surgical insult. A carefully restricted list of procedures was used; complex cases were excluded, as were urgent or emergency operations, and any with >500 ml estimated intraoperative haemorrhage or where blood product transfusion was required.

To reduce artificial bias further, the authors also disregarded procedures of <60 min duration, which might increase the overall milligram per kilogram per hour figure as a result of 'frontloading', patients looked after by student nurse anaesthetists, and all episodes by providers or surgeons with fewer than six patients in the registry.

This well-reasoned approach to the analysis resulted in a relatively homogeneous cohort. Nevertheless, the distribution of perioperative fluid volumes given was very wide.

This paper makes for quite uncomfortable reading.

1 of 6

But These Data Don't Apply to Me

Can we claim that US perioperative clinical practice differs too much from ours for the headline observations from this study to be relevant to European practice? The model of anaesthesia care is somewhat different; in these hospitals, a licenced 'attending' anaesthesiologist supervises anaesthesia provision by either a certified registered nurse anaesthestist ('CRNA'; who comprised just under half of the in-room providers in this study) or medically trained residents (the remainder). No patients who received fluid therapy from a student registered nurse anaesthestist were included, on the basis that only one of the two institutions had them. In the UK, intraoperative cardiac output monitoring to guide stroke volume optimization during many elective major surgeries is recommended by the National Institute for Health and Care Excellence (NICE)[6] and advocated as a means to achieve bespoke fluid therapy for the individual, but this has gained little traction in America as yet. The authors of this paper specifically mention that goal-directed fluid therapy was not practised. Also omitted is information about perioperative vasoactive drug use. Vasopressors may be used as part of 'balanced' haemodynamic therapy during surgery and are likely to have an impact on the fluid volumes used.

But there are broad similarities between the health-care models in the two continents. With the advent of the 'perioperative surgical home' in the USA, elective surgical services increasingly resemble Europe's enhanced recovery.[7] If anything, outcomes from leading US hospitals are often better than ours for similar procedures.[8]

Is the variability unique to the two institutions in this study? No! Registry data for a period of 5 yr from more than half a million patients having colonic or arthroplasty surgery confined to nine ICD-9 procedure codes across 524 US hospitals shows that fluid usage complies to a U-shaped curve, with a median of around 3 litres crystalloid per procedure; however, the interquartile range of intraoperative fluid administration ranges from 1.3 to 5.0 litres, and varies by institution. A quarter of colonic surgery patients received >5 litres on the day of surgery and 11 litres postoperatively.[9]

In the UK, it is likely that there is similar variability in 'standard care' across providers and institutions. This is certainly apparent in UK perioperative fluid therapy studies. Recommended control group baseline fluid regimens in recent prominent trials have ranged from dextrose water 5% (1 ml kg−1 h−1)[10] to isotonic crystalloid (10 ml kg−1 h−1).[11] Consensus guidelines from England's Enhanced Recovery Partnership Programme recommend that maintenance fluid during surgery should be limited to <2 ml kg−1 h−1, with further fluid challenges guided by stroke volume monitoring;[12] several state-of-the-art recent fluid therapy studies[13] have used no baseline crystalloid at all. It seems unlikely that both ends of this spectrum of current common clinical practice are correct (Fig. 1).

Hourly water and solute load of two i.v. fluid maintenance regimens commonly used in clinical practice. For a 70 kg patient, dextrose water 5% administered at 1.5 ml kg−1 h−1 (lower left) contains the equivalent of two 50 ml syringes of water and 5 g dextrose (approximate sugar content of a small handful of raisins). In contrast, 10 ml kg−1 h−1 is the equivalent of fourteen 50 ml syringes of water and the salt content of ten 32.5 g bags of crisps. (Image courtesy of Department of Medical Photography, Derriford Hospital.)



Does All This Variability Have Any Consequences?

We cannot answer that from the data in the paper. No clinical outcomes are reported.

However, experience from enhanced recovery (ER)/'perioperative surgical home' programmes is likely to be relevant.[14] Great improvements in perioperative outcome can be achieved through adherence to simple management processes, seeking to iron out inconsistency in practice. The more elements achieved, the better the outcome. For elective abdominal surgery, of around 20 elements, avoidance of fluid overload is one of the key two (the other is provision of preoperative carbohydrate drinks).[15] The amount of i.v. fluid given is inversely proportional to postoperative complications. In a prospective cohort study of 953 colorectal cancer patients, for every 1 litre excess fluid given on the day of surgery, a 32% increase was seen in measured postoperative complications. This theme is echoed in the UK ER literature. Deviation from an ER pathway is associated with an increase in length of stay; continued i.v. fluid administration past the first postoperative day is strongly associated with delayed discharge (OR=4.80, 95% confidence interval 3.02–7.75).[16] It is important not to be disingenuous about this association. An obvious argument is that 'excess' postoperative fluid is a marker of mischief, rather than its cause; for example, the drip stays up on the patient with an intestinal ileus who is vomiting and apparently unable to drink. But it is likely that also included in the delayed discharge group are many patients who receive excess i.v. fluid simply because it is 'standard practice.'

Developing Consistency

Is consistency achievable across a multitude of clinicians? Certainly! A recent trial of fluid and salt restriction vs a liberal controlled perioperative fluid regimen in 240 patients undergoing elective abdominal surgery managed to deliver intraoperative median fluid volumes of around 1 or 2 litres, respectively, with interquartile ranges of <500 ml either way.[17]

It is interesting that in the paper by Lilot and colleagues,[5] the mean fluid administration rate for ASA I patients was 9.9 (SD6.2) ml kg−1 h−1 with a cCOV of 87%, whereas for ASA III patients it was 6.9 (SD 4.7) ml kg−1 h−1, a cCOV of 66%. Is this indicative of closer attention being paid to patients who are perceived as sicker?

For colorectal surgery carried out within an ER model of minimal physiological upset, a 'zero balance' approach appears to be as effective as 'stroke volume optimization' in terms of achieving good clinical outcomes. This means bringing patients to theatre in a euvolaemic state, then paying meticulous attention to detail in fluid administration.[18] Let's be clear; this is not evidence that stroke volume optimization does not work. 'Zero balance' is not easy to do, and in all likelihood it bears little resemblance to current standard practice in most hospitals.

Does it take something unique or special to reduce inter and intraprovider variability in this manner? Experienced anaesthetists claim that there is no substitute for their clinical judgement. There is some evidence for this. Two recent large multicentre effectiveness randomized controlled trials of early goal-directed therapy for patients admitted to the emergency department with severe sepsis have returned the same result; that strictly protocolized management targeted at defined haemodynamic milestones is no better than judicious sustained care delivered by experienced clinicians.[19] However, the end points that senior clinicians use to realize such results may be subtle, whereas care on the front line is often delivered by relatively junior doctors or by nursing staff following a protocol. Additional information provided by minimally invasive advanced haemodynamic monitors could be a useful adjunct to assist understanding of the volaemic status of individual patients, effectively allowing inexperienced staff to emulate the artistry of the masters through painting by numbers.

What Does Good Perioperative Fluid Practice Look Like?

British Consensus Guidelines for Intravenous Fluid Therapy in Adult Surgical Patients[20] recommend that whenever we give fluid (and salt) for correction of a volume deficit during major surgery it should be directed towards a particular goal. Goals may (or may not) be a nominal cardiac stroke volume or related index of blood flow.

The consensus statement from the Department of Health's Enhanced Recovery Partnership Programs (ERPP) on perioperative fluid therapy makes a similar recommendation regarding goal-directed therapy.[12] Whatever the goals and however they are attained, it is important that providers remain focused on them throughout the operation.

An underappreciated facet of perioperative care is that much of the i.v. fluid that patients receive during a surgical admission is delivered postoperatively. In contrast to the intraoperative setting, many hospitals leave delivery of this to nurses and surgical juniors. In December 2013, NICE published 'clinical guideline 174', entitled 'Intravenous fluid therapy in adults in Hospital.'[21] The introduction says:

… the recommendations do not apply … to patients needing inotropes and those on intensive monitoring, and so they have less relevance to intensive care settings and patients during surgical anaesthesia …

NICE 174 are thus broadly intended for non-expert first responders, such as trainee doctors on call out of hours. That should not mean we, as perioperative physicians, can ignore them. We need to be accountable for this territory. As self-proclaimed experts in perioperative care, it is our responsibility to prescribe an appropriate fluid in an appropriate volume for postoperative care and to participate in consistent education of those entrusted with front-line delivery of this. In the modern multidisciplinary era, much postoperative care is directly delivered by nursing staff, who are very capable of following algorithms to achieve good clinical outcomes.[22]

NICE 174, GIFTASUP and the ERPP consensus statements are highly relevant to perioperative fluid therapy, although all three have been controversial[23] as a result of perceived alignment with particular advanced haemodynamic monitors or fluids. Whilst some recommendations are limited by the absence of conclusive evidence,[24] according to our reading, the important common elements in the consensus statements are as follows: (i) fluid management is important and when done badly causes very significant harm.

(ii) Outcomes are better when algorithms, guidelines and regular audit are used to guide care.

Best-practice algorithms are elusive. There is some primary and systematic review literature in favour of a more restrictive approach to perioperative fluid therapy,[25,26] in keeping with the current view that third space loss does not occur, but the 'definitive' large multicentre trial, RELIEF, currently recruiting, is unlikely to report results before 2017 [http://www.relief.org.au/ (accessed 18 November 2014)]. This will be the largest perioperative fluid study to date, a randomized controlled trial of liberal vs restrictive fluid therapy in >2800 patients undergoing elective intra-abdominal surgery. Many UK hospitals have declined involvement on the basis that they consider the question resolved in favour of restrictive and consider themselves to practice this already.

But do you really know how much fluid you give? It is not clear that all these hospitals collect data on their fluid practice. It is striking that in a prominent goal-directed therapy study, isotonic crystalloid maintenance at 10 ml kg−1 was advised, perhaps already an excessively liberal baseline regimen, yet attending anaesthetists gave on average 17 ml kg−1 h−1 to the elective colorectal surgery patients enrolled in the trial.[11]

The perpetual cycle of quality improvement relies on embedded collection and continuous feedback of reliable data. This allows services to know how they are really performing (rather than how they think they are).

(iii) It is of practical use to distinguish 'R'esuscitation from 'R'eplacement from 'R'egular maintenance in deciding the volume and type of fluid to use. Definitions are difficult, there being considerable overlap between the four phases of fluid therapy relevant to acute patients as mentioned above. Clinical application may be even more difficult because we do not know what the best end points and algorithms are.

Resuscitation is restoration of circulating volume to above a critical perfusion threshold[27] and is achieved with isotonic colloid, crystalloid, or where appropriate, blood and blood products.

Replacement is likewise targeted, bespoke, and difficult. We believe that careful measurement and replacement of losses with fluid of a similar composition makes biological sense. Advanced haemodynamic monitoring may assist in achieving this aim.

However, we wish to conclude this commentary by focusing on maintenance fluid therapy, particularly after surgery.

What Should We Hang After Surgery?

We currently 'hang salt by default.' This is irrational. Consider our model of electrolyte and fluid homeostasis in the human organism after a physiological stress, such as major surgery. The body is avidly holding on to salt and water.[28] Does it make sense to infuse yet more?

If patients receive consistently judged intraoperative fluid therapy and arrive at the end of surgery euvolaemic, it seems appropriate to provide ~1 ml kg−1 h−1 or less afterwards. And why should we not hang dextrose water 5% as our baseline maintenance, reserving isotonic crystalloids for replacement of losses?

Lactated Ringer solution and normal saline are not maintenance solutions, because their sodium content is much too high for this purpose. A single litre bag of Hartmann's solution contains around twice the recommended daily intake of sodium chloride. Accordingly, three bags of this stuff hung as daily maintenance creates a large salt load. On a cautionary note, we emphasize that no more than 2 litres per day of dextrose water 5% should be infused and that i.v. maintenance should be taken down as soon as patients are drinking freely.[29] If a patient remains nil by mouth for an extended period for clinical reasons then electrolytes should be checked; in this situation, dextrose saline with potassium is a reasonable choice if plasma sodium is normal and 'routine maintenance' is the aim.

Can we as a clinical community agree? I.V. fluids should be administered with the same rigour as with any other drug. We have been researching perioperative fluid therapy for a very long time, yet because of inconsistent trial design we are no closer to the truth. In the absence of clearer evidence, in our view fluid management according to the standard practice group in the OPTIMISE trial is a reasonable approach to adopt for current best practice.[10] It may be true that aspects of expert consensus guidelines are controversial,[24] but surely treatment according to individual provider habit is even harder to justify? An acceptable alternative is that hospitals produce their own local perioperative fluid guidelines based on reliable local audit. But continued apathy is not the answer.












Posted by 돈오돈오
,



http://www.medscape.com/viewarticle/844820


Best Evidence Yet!: Ejaculation Reduces Prostate Cancer Risk

Nick Mulcahy

May 17, 2015

NEW ORLEANS — Good news, men: you may be able to decrease your risk for prostate cancer by ejaculating — frequently, according to research presented here at American Urological Association 2015 Annual Meeting.

The frothy advice is not new but is now backed up by the "strongest evidence to date" on the subject, according to lead author Jennifer Rider, ScD, MPH, an epidemiologist at the Harvard T.H. Chan School of Public Health in Boston.

"There is no modifiable risk factor for developing prostate cancer," Dr Rider told Medscape Medical News. "It would be exciting to tell men that there was a way to modify their risk."

However, she noted that these are observational data and urged caution when "interpreting them."

The results are "fascinating," said Jesse Sammon, MD, a urologist at the Henry Ford Hospital in Detroit, who attended Dr Rider's presentation. "It was the highlight of the session on cancer epidemiology; the moderator called it the 'study most likely to be tweeted'."

These are "incredibly high-quality data," said Dr Sammon, who was not involved with the study.

The data come from nearly 32,000 men in the prospective Health Professionals Follow-up Study, who now have been followed for 18 years.

During the study period, 3839 men have been diagnosed with incident prostate cancer, 384 cases of which were lethal.

At recruitment in 1992, all participating men were asked to report their average monthly frequency of ejaculation from the ages of 20 to 29 years and 40 to 49 years, and during the previous year. A lifetime average was then computed from these reports.

After potential confounders were controlled for, the risk for prostate cancer was 20% lower in men who ejaculated at least 21 times a month than in men who ejaculated 4 to 7 times a month. The 20% risk reduction was seen at ages 20 to 29 and 40 to 49, and for the lifetime average (P trend < .0001 for all).

At ages 40 to 49, men most (38.0%) reported 8 to 12 ejaculations per month; only 8.8% reported at least 21 ejaculations per month.

"We shouldn't dwell on the exact numbers of ejaculation, but instead should focus on the dose–response relation," Dr Rider advised.

She summarized: "Safe sexual activity could be good for prostate health."

Notably, there was no association between ejaculation frequency and the risk for high-grade, advanced, or lethal disease, she reported. The reason for this exception is not known.

These results are an update of the last major report from the Health Professionals Follow-up Study, which was published about 10 years ago (JAMA2004;291:1578-1586). At that time, investigators concluded that "high ejaculation frequency may possibly be associated with a lower risk of total and organ-confined prostate cancer," as reported by Medscape Medical News.

Many other studies have likewise reported that ejaculation frequency might be tied to prostate cancer risk, with more orgasms being protective.

But these new data have three outstanding strengths, Dr Rider said.

First, the study is prospective, whereas most other studies have been retrospective, and the data are long term. Second, the study involves the largest cohort to date. And third, the study has specific information on ejaculation, she explained.

Whereas previous studies have tended to rely on "proxies" for ejaculation, such as age at marriage, number of children, and number of sex partners, the Health Professionals Follow-up Study investigators were bold; they explicitly asked about ejaculations from sexual intercourse, masturbation, and nocturnal emissions.

The average age of the men in the study was about 59 years, and they had undergone an average of five PSA tests by 2008. Most of the men were married, but the men who reported at least 21 ejaculations per month at ages 40 to 49 were more likely to be divorced than less robust ejaculators (11.8% vs 4% - 7%).

American Urological Association (AUA) 2015 Annual Meeting: Abstract PD6-07. Presented May 15, 2015.


Posted by 돈오돈오
,